Sign in to continue:

Saturday, March 28th, 2026

Amarin Corporation plc 8-K Filing March 2026: Director Changes and Compensation Policy Update

Amarin Corporation plc Announces Updates to Non-Employee Director Compensation Policy

Key Points:

  • Amarin Corporation plc (NASDAQ: AMRN) has announced an amendment and restatement of its Non-Employee Director Compensation Policy, effective March 25, 2026.
  • The update includes changes to the structure and timing of annual equity awards for non-employee directors and clarifies the vesting terms related to such awards.
  • The policy also provides details on cash and equity retainer choices, committee chair and member fees, and initial equity awards for new directors.
  • This update may have implications on the company’s governance practices and could impact the attractiveness of board positions, potentially influencing the share price.

Details of the Amended Non-Employee Director Compensation Policy

Amarin Corporation plc’s Board of Directors has approved significant changes to the compensation policy for non-employee directors as part of its ongoing corporate governance review. The revised policy aims to align director incentives with shareholder interests and market practices.

Annual Equity Awards

  • Each non-employee director will be eligible for an annual equity award consisting of Restricted Stock Units (RSUs) and Options, as defined in the Company’s 2020 Stock Incentive Plan (as amended).
  • These equity awards will vest in full upon the earlier of either the one-year anniversary of the grant date (which will coincide with the date of Amarin’s annual general meeting of shareholders) or the date of the annual general meeting in the following year.
  • This vesting schedule is designed to align directors’ interests with the Company’s long-term performance and incentivize retention.

Annual Retainer and Committee Fees

  • The policy provides for an annual retainer fee for non-employee directors, with specific additional fees for serving as Chair or member of key committees:
    • All Non-Employee Directors (other than Non-Executive Chair): \$95,000 annual retainer
    • Audit Committee Chair: \$25,000
    • Remuneration Committee Chair: \$20,000
    • Nominating and Corporate Governance Committee Chair: \$11,000
    • Audit Committee Member: \$12,000
    • Remuneration Committee Member: \$10,000
    • Nominating and Corporate Governance Committee Member: \$5,000

Form of Payment Election

  • Non-employee directors may elect, within 10 days after the end of each calendar quarter, to receive their annual retainers in either cash or unregistered non-American Depositary Shares (ADSs).
  • Each ADS represents the right to receive 20 ordinary shares of Amarin Corporation.
  • The price for share-based retainers will be the higher of (a) the closing price of Amarin’s ADSs on Nasdaq 10 calendar days after the end of the quarter or (b) GBP £0.50 per ordinary share, multiplied by 20.

Initial Equity Awards for New Directors

  • Upon initial appointment, non-employee directors will receive an equity award valued at \$262,500, split 75% in share options and 25% in restricted share units.
  • Options vest one-third on the first anniversary of the grant date and in equal quarterly installments over the next two years.
  • The option exercise price is the greater of (a) the Nasdaq closing price on the grant date or (b) GBP £0.50 per share, multiplied by 20.

Change of Control Provisions

  • If a “Change of Control” event (as defined in the Stock Incentive Plan) occurs, all outstanding share options and RSU awards for non-employee directors will immediately become fully vested.
  • If a Change of Control occurs before the 2026 Annual Meeting, new non-employee directors will receive a lump-sum cash payment of \$262,500 instead of the initial equity award.

Other Compensation

  • Non-employee directors will be reimbursed for reasonable out-of-pocket expenses related to attending Board and committee meetings.

Potential Shareholder Impact and Price Sensitivity

  • Governance and Alignment: The revised policy aligns director compensation more closely with shareholder interests and long-term performance, which may be viewed positively by governance-focused investors.
  • Attracting Talent: Enhanced equity compensation and flexibility in retainer payments may make Amarin’s board positions more attractive, supporting the Company’s ability to recruit and retain qualified directors.
  • Change of Control: The acceleration of vesting and cash payments in a Change of Control scenario could be significant in the context of M&A activity, potentially impacting share value expectations if investors anticipate strategic transactions.

Other Filings and Corporate Information

  • No written communications, soliciting material, or pre-commencement tender offer communications are associated with this filing.
  • Amarin Corporation plc’s American Depositary Shares (ADS), each representing 20 ordinary shares, are listed on the Nasdaq Stock Market under the symbol AMRN.
  • The company’s principal executive offices are located at SPACES SOUTH DOCKLANDS, BLOCK C, 77 SIR JOHN ROGERSON’S QUAY, DUBLIN 2, Ireland.

Conclusion

This update to the Director Compensation Policy is material information for shareholders as it could influence the governance direction, director incentives, and potentially the Company’s attractiveness in the event of strategic activity. Investors should consider these changes when evaluating Amarin’s leadership alignment and its implications for future performance and share value.



Disclaimer: This article is for informational purposes only and does not constitute investment advice. Shareholders and potential investors should conduct their own due diligence and consult with professional advisors before making investment decisions. The information provided is based on the company’s public filings as of March 25, 2026, and may be subject to further updates.


View AMARIN CORP PLCUK Historical chart here



Arbutus Biopharma 2025 Annual Report: Clinical Pipeline, Patent Litigation, and Strategic Outlook

Arbutus Biopharma Corp 2025 Annual Report: Key Investor High...

Finance of America Companies Inc. 2025 Annual Report: Financial Statement, SEC Filing, and Company Overview

Finance of America Companies Inc. 2025 Annual Report - Inves...

   Ad